



General Assembly

**Substitute Bill No. 5042**

February Session, 2014



**AN ACT CONCERNING THE REGENERATIVE MEDICINE RESEARCH FUND.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. Subsection (a) of section 19a-32d of the 2014 supplement  
2 to the general statutes is repealed and the following is substituted in  
3 lieu thereof (*Effective October 1, 2014*):

4 (a) As used in sections 19a-32d to 19a-32g, inclusive, as amended by  
5 this act, and section 4-28e, as amended by this act:

6 (1) "Embryonic stem cell research oversight committee" means a  
7 committee established in accordance with the National Academies'  
8 Guidelines for Human Embryonic Stem Cell Research, as amended  
9 from time to time.

10 (2) "Cloning of a human being" means inducing or permitting a  
11 replicate of a living human being's complete set of genetic material to  
12 develop after gastrulation commences.

13 (3) "Gastrulation" means the process immediately following the  
14 blastula state when the hollow ball of cells representing the early  
15 embryo undergoes a complex and coordinated series of movements  
16 that results in the formation of the three primary germ layers, the  
17 ectoderm, mesoderm and endoderm.

18 (4) "Embryonic stem cells" means cells created through the joining of  
19 a human egg and sperm or through nuclear transfer that are  
20 sufficiently undifferentiated such that they cannot be identified as  
21 components of any specialized cell type.

22 (5) "Nuclear transfer" means the replacement of the nucleus of a  
23 human egg with a nucleus from another human cell.

24 (6) "Eligible institution" means (A) a nonprofit, tax-exempt academic  
25 institution of higher education, (B) a hospital that conducts biomedical  
26 research, or (C) any entity that conducts biomedical research or  
27 [embryonic or human adult stem cell] regenerative medicine research.

28 (7) "Regenerative medicine" means the process of creating living,  
29 functional tissue to repair or replace tissue or organ function lost due  
30 to aging, disease, damage or congenital defect. Regenerative medicine  
31 includes basic stem cell research.

32 Sec. 2. Section 19a-32e of the general statutes is repealed and the  
33 following is substituted in lieu thereof (*Effective October 1, 2014*):

34 (a) There is established the ["Stem Cell Research Fund"]  
35 "Regenerative Medicine Research Fund", which shall be a separate,  
36 nonlapsing account within the General Fund. The fund may contain  
37 any moneys required or permitted by law to be deposited in the fund  
38 and any funds received from any public or private contributions, gifts,  
39 grants, donations, bequests or devises to the fund. [The Commissioner  
40 of Public Health may] The chief executive officer of Connecticut  
41 Innovations, Incorporated, (1) shall make grants-in-aid from the fund  
42 in accordance with the provisions of subsection (b) of this section, and  
43 (2) may enter into agreements with other entities, including, but not  
44 limited to, the government of any state or foreign country for the  
45 purpose of advancing research collaboration opportunities for  
46 recipients of grants-in-aid under this section.

47 (b) [Not later than June 30, 2006, the Stem Cell] The Regenerative  
48 Medicine Research Advisory Committee established pursuant to

49 section 19a-32f, as amended by this act, shall develop an application  
50 for grants-in-aid under this section for the purpose of conducting  
51 [embryonic or human adult stem cell] regenerative medicine research  
52 and may receive applications from eligible institutions for such grants-  
53 in-aid. [on and after said date. The Stem Cell] The Regenerative  
54 Medicine Research Advisory Committee shall require any applicant  
55 for a grant-in-aid under this section to conduct [stem cell] regenerative  
56 medicine research to submit (1) a complete description of the  
57 applicant's organization, (2) the applicant's plans for [stem cell]  
58 regenerative medicine research and proposed funding for such  
59 research from sources other than the state, [of Connecticut,] and (3)  
60 proposed arrangements concerning financial benefits to the state [of  
61 Connecticut] as a result of any patent, royalty payment or similar  
62 rights developing from any [stem cell] proposed research made  
63 possible by the awarding of such grant-in-aid. [Said committee shall  
64 direct the Commissioner of Public Health] The Regenerative Medicine  
65 Research Advisory Committee shall direct the chief executive officer of  
66 Connecticut Innovations, Incorporated, with respect to the awarding of  
67 such grants-in-aid after considering recommendations from the [Stem  
68 Cell] Regenerative Medicine Research Peer Review Committee  
69 established pursuant to section 19a-32g, as amended by this act.

70 (c) Commencing with the fiscal year ending June 30, 2006, and for  
71 each of the [nine] fourteen consecutive fiscal years thereafter, until the  
72 fiscal year ending June 30, [2015] 2020, not less than ten million dollars  
73 shall be available from the [Stem Cell] Regenerative Medicine Research  
74 Fund for grants-in-aid to eligible institutions for the purpose of  
75 conducting [embryonic or human adult stem cell research, as directed  
76 by the Stem Cell Research Advisory Committee established pursuant  
77 to section 19a-32f] regenerative medicine research. Any balance of such  
78 amount not used for such grants-in-aid during a fiscal year shall be  
79 carried forward for the fiscal year next succeeding for such grants-in-  
80 aid.

81 Sec. 3. Section 19a-32f of the general statutes is repealed and the

82 following is substituted in lieu thereof (*Effective October 1, 2014*):

83 (a) (1) There is established a [Stem Cell] Regenerative Medicine  
84 Research Advisory Committee. The committee shall consist of the  
85 Commissioner of Public Health, or the commissioner's designee, the  
86 chief executive officer of Connecticut Innovations, Incorporated, or the  
87 chief executive officer's designee, and eight members who shall be  
88 appointed as follows: Two by the Governor, [one of whom shall be  
89 nationally recognized as an active investigator in the field of stem cell  
90 research and one of whom shall have background and experience in  
91 the field of bioethics] who shall have backgrounds and experience in  
92 embryonic stem cell or regenerative medicine research; one each by the  
93 president pro tempore of the Senate and the speaker of the House of  
94 Representatives, who shall have background and experience in private  
95 sector [stem cell] regenerative medicine research and development;  
96 one each by the majority leaders of the Senate and House of  
97 Representatives, who shall be academic researchers specializing in  
98 [stem cell] regenerative medicine research; one by the minority leader  
99 of the Senate, who shall have background and experience in either  
100 private or public sector [stem cell] regenerative medicine research and  
101 development or related research fields, including, but not limited to,  
102 embryology, genetics or cellular biology; and one by the minority  
103 leader of the House of Representatives, who shall have background  
104 and experience in business or financial investments. Members shall  
105 serve for a term of four years commencing on October first, except that  
106 members first appointed by the Governor and the majority leaders of  
107 the Senate and House of Representatives shall serve for a term of two  
108 years. No member may serve for more than two consecutive four-year  
109 terms and no member may serve concurrently on the [Stem Cell]  
110 Regenerative Medicine Research Peer Review Committee established  
111 pursuant to section 19a-32g, as amended by this act. All initial  
112 appointments to the committee shall be made by October 1, 2005. Any  
113 vacancy shall be filled by the appointing authority.

114 (2) On and after July 1, 2006, the [advisory committee] Regenerative

115 Medicine Research Advisory Committee shall include eight additional  
116 members who shall be appointed as follows: Two by the Governor,  
117 [one of whom shall be nationally recognized as an active investigator  
118 in the field of stem cell research and one of whom shall have  
119 background and experience in the field of ethics] who shall have  
120 backgrounds and experience in business, law or ethics; one each by the  
121 president pro tempore of the Senate and the speaker of the House of  
122 Representatives, who shall have background and experience in private  
123 sector [stem cell] regenerative medicine research and development;  
124 one each by the majority leaders of the Senate and House of  
125 Representatives, who shall be academic researchers specializing in  
126 [stem cell] regenerative medicine research; one by the minority leader  
127 of the Senate, who shall have background and experience in either  
128 private or public sector [stem cell] regenerative medicine research and  
129 development or related research fields, including, but not limited to,  
130 embryology, genetics or cellular biology; and one by the minority  
131 leader of the House of Representatives, who shall have background  
132 and experience in business or financial investments. Members shall  
133 serve for a term of four years, except that (A) members first appointed  
134 by the Governor and the majority leaders of the Senate and House of  
135 Representatives pursuant to this subdivision shall serve for a term of  
136 two years and three months, and (B) members first appointed by the  
137 remaining appointing authorities shall serve for a term of four years  
138 and three months. No member appointed pursuant to this subdivision  
139 may serve for more than two consecutive four-year terms and no such  
140 member may serve concurrently on the [Stem Cell] Regenerative  
141 Medicine Research Peer Review Committee established pursuant to  
142 section 19a-32g, as amended by this act. All initial appointments to the  
143 committee pursuant to this subdivision shall be made by July 1, 2006.  
144 Any vacancy shall be filled by the appointing authority.

145 [(b) The Commissioner of Public Health, or the commissioner's  
146 designee, shall serve as the chairperson of the committee and shall  
147 schedule the first meeting of the committee, which shall be held no  
148 later than December 1, 2005.]

149     (b) The chief executive officer of Connecticut Innovations,  
150 Incorporated, or the chief executive officer's designee, shall serve as  
151 chairperson of the Regenerative Medicine Research Advisory  
152 Committee.

153     (c) All members appointed to [the] said advisory committee shall  
154 work to advance [embryonic and human adult stem cell] regenerative  
155 medicine research. Any member who fails to attend three consecutive  
156 meetings or who fails to attend fifty per cent of all meetings held  
157 during any calendar year shall be deemed to have resigned from [the]  
158 said advisory committee.

159     (d) Notwithstanding the provisions of any other law, it shall not  
160 constitute a conflict of interest for a trustee, director, partner, officer,  
161 stockholder, proprietor, counsel or employee of any eligible institution,  
162 or for any other individual with a financial interest in any eligible  
163 institution, to serve as a member of [the] said advisory committee. All  
164 members shall be deemed public officials and shall adhere to the code  
165 of ethics for public officials set forth in chapter 10. Members may  
166 participate in the affairs of [the] said advisory committee with respect  
167 to the review or consideration of grant-in-aid applications, including  
168 the approval or disapproval of such applications, except that no  
169 member shall participate in the affairs of [the] said advisory committee  
170 with respect to the review or consideration of any grant-in-aid  
171 application filed by such member or by any eligible institution in  
172 which such member has a financial interest, or with whom such  
173 member engages in any business, employment, transaction or  
174 professional activity.

175     (e) The [Stem Cell] Regenerative Medicine Research Advisory  
176 Committee shall (1) develop, in consultation with [the Commissioner  
177 of Public Health] Connecticut Innovations, Incorporated, a donated  
178 funds program to encourage the development of funds other than state  
179 appropriations for [embryonic and human adult stem cell]  
180 regenerative medicine research in [this] the state, (2) examine and  
181 identify specific ways to improve and promote for-profit and not-for-

182 profit [embryonic and human adult stem cell] regenerative medicine  
183 research and [related] research in related areas in the state, including,  
184 but not limited to, identifying both public and private funding sources  
185 for such research, maintaining existing [embryonic and human adult  
186 stem-cell-related] regenerative medicine-related businesses, recruiting  
187 new [embryonic and human adult stem-cell-related] regenerative  
188 medicine-related businesses to the state and recruiting scientists and  
189 researchers in such field to the state, (3) [establish and] administer, in  
190 consultation with the [Commissioner of Public Health] Bioscience  
191 Innovation Advisory Committee and Connecticut Innovations,  
192 Incorporated, a [stem cell] regenerative medicine research grant  
193 program [which] that shall provide grants-in-aid to eligible institutions  
194 for the advancement of [embryonic or human adult stem cell]  
195 regenerative medicine research in [this] the state pursuant to section  
196 19a-32e, [and] as amended by this act, (4) monitor the [stem cell]  
197 regenerative medicine research conducted by eligible institutions that  
198 receive such grants-in-aid, and (5) prepare a comprehensive strategic  
199 plan for the Regenerative Medicine Research Fund, established  
200 pursuant to section 19a-32e, as amended by this act, and grants-in-aid  
201 made from said fund that shall include, but need not be limited to,  
202 identification of specific methods or strategies to (A) achieve the  
203 scientific and economic development objective of said fund, (B) build  
204 innovation capacity, and (C) sustain investments of moneys received  
205 by said fund.

206 (f) Connecticut Innovations, Incorporated, shall serve as  
207 administrative staff of the [committee] Regenerative Medicine  
208 Research Advisory Committee and shall assist [the] said advisory  
209 committee in: (1) [developing] Developing the application for the  
210 grants-in-aid authorized under subsection [(e) of this section,] (b) of  
211 section 19a-32e, as amended by this act; (2) reviewing such  
212 applications; [,] (3) reviewing recommendations of the Regenerative  
213 Medicine Research Peer Review Committee, established pursuant to  
214 section 19a-32g, as amended by this act; (4) preparing and executing  
215 any assistance agreements or other agreements in connection with the

216 awarding of such grants-in-aid; [ and (4)] (5) developing performance  
217 metrics and systems to collect data from recipients of such grants-in-  
218 aid; (6) collecting information from recipients of such grants-in-aid  
219 concerning each recipient's (A) employment statistics, (B) business  
220 accomplishments and performance outcomes, (C) peer review articles  
221 and papers published, (D) partnerships and collaborations with other  
222 entities, (E) licenses, patents and invention disclosures, (F) scientific  
223 progress as it relates to the commercialization of intellectual property  
224 funded by such grants-in-aid, (G) efforts to commercialize such  
225 intellectual property, and (H) other funds received for research; and (7)  
226 performing such other administrative duties as the [committee]  
227 Regenerative Medicine Research Advisory Committee deems  
228 necessary.

229 Sec. 4. Section 19a-32g of the general statutes is repealed and the  
230 following is substituted in lieu thereof (*Effective October 1, 2014*):

231 (a) (1) There is established a [Stem Cell] Regenerative Medicine  
232 Research Peer Review Committee. [The] Said peer review committee  
233 shall consist of five members. [appointed by the Commissioner of  
234 Public Health. All]

235 (2) On and before September 30, 2014, all members appointed by the  
236 Commissioner of Public Health to the committee shall (A) have  
237 demonstrated knowledge and understanding of the ethical and  
238 medical implications of [embryonic and human adult stem cell]  
239 regenerative medicine research or related research fields, including,  
240 but not limited to, embryology, genetics or cellular biology, (B) have  
241 practical research experience in [human adult or embryonic stem cell]  
242 regenerative medicine research or related research fields, including,  
243 but not limited to, embryology, genetics or cellular biology, and (C)  
244 work to advance [embryonic and human adult stem cell] regenerative  
245 medicine research. Members shall serve for a term of four years  
246 commencing on October first, except that three members first  
247 appointed by the Commissioner of Public Health shall serve for a term  
248 of two years. No member may serve for more than two consecutive



four-year terms and no member may serve concurrently on the [Stem Cell] Regenerative Medicine Research Advisory Committee established pursuant to section 19a-32f, as amended by this act. All initial appointments to [the] said peer review committee shall be made by October 1, 2005. Any member who fails to attend three consecutive meetings or who fails to attend fifty per cent of all meetings held during any calendar year shall be deemed to have resigned from [the] said peer review committee.

[(2) The Commissioner of Public Health may appoint such additional members to the Stem Cell Research Peer Review Committee as the commissioner deems necessary for the review of applications for grants-in-aid, provided the total number of Stem Cell Research Peer Review Committee members does not exceed fifteen. Such additional members shall be appointed as provided in subdivision (1) of this subsection, except that such additional members shall serve for a term of two years from the date of appointment.]

(3) On and after October 1, 2014, each member appointed by the Commissioner of Public Health pursuant to subdivision (2) of this subsection may serve to the conclusion of his or her current term at which time members shall be appointed by the chief executive officer of Connecticut Innovations, Incorporated, as follows: Members appointed to said peer review committee shall: (A) Have demonstrated knowledge and understanding of the ethical and medical implications of regenerative medicine research or research in a related field, including, but not limited to, embryology, genetics or cellular biology; (B) have practical research experience in regenerative medicine research or research in a related field, including, but not limited to, embryology, genetics or cellular biology; and (C) work to advance regenerative medicine research. Members shall serve for a term of four years, except that three members first appointed by the chief executive officer of Connecticut Innovations, Incorporated, shall serve for a term of two years. No member may serve for more than two consecutive four-year terms and no member may serve concurrently on the

282 Regenerative Medicine Research Advisory Committee established  
283 pursuant to section 19a-32f, as amended by this act. Any member who  
284 fails to attend three consecutive meetings or who fails to attend fifty  
285 per cent of all meetings held during any calendar year shall be deemed  
286 to have resigned from said peer review committee.

287 (b) All members shall be deemed public officials and shall adhere to  
288 the code of ethics for public officials set forth in chapter 10. No  
289 member shall participate in the affairs of the committee with respect to  
290 the review or consideration of any grant-in-aid application filed by  
291 such member or by any eligible institution in which such member has  
292 a financial interest, or with which such member engages in any  
293 business, employment, transaction or professional activity.

294 (c) Prior to the awarding of any grants-in-aid for [embryonic or  
295 human adult stem cell] regenerative medicine research pursuant to  
296 section 19a-32e, as amended by this act, the [Stem Cell] Regenerative  
297 Medicine Research Peer Review Committee shall review all  
298 applications submitted by eligible institutions for such grants-in-aid  
299 and make recommendations to the [Commissioner of Public Health  
300 and the Stem Cell] Regenerative Medicine Research Advisory  
301 Committee established pursuant to section 19a-32f, as amended by this  
302 act, with respect to the ethical and scientific merit of each application.

303 (d) [Peer review committee members] Members of the Regenerative  
304 Medicine Research Peer Review Committee may receive compensation  
305 from [the Stem Cell Research Fund, established pursuant to section  
306 19a-32e,] Connecticut Innovations, Incorporated, for reviewing grant-  
307 in-aid applications submitted by eligible institutions. [pursuant to  
308 subsection (c) of this section.] The rate of compensation shall be  
309 established by the [Commissioner of Public Health in consultation  
310 with the Department of Administrative Services and the Office of  
311 Policy and Management] board of directors of Connecticut  
312 Innovations, Incorporated.

313 (e) The Regenerative Medicine Research Peer Review Committee

314 shall establish guidelines for the rating and scoring of such  
315 applications. [by the Stem Cell Research Peer Review Committee.]

316 (f) All members of [the] said peer review committee shall become  
317 and remain fully cognizant of the National Academies' Guidelines for  
318 Human Embryonic Stem Cell Research, as amended from time to time,  
319 and shall utilize said guidelines to evaluate each grant-in-aid  
320 application. [The committee may make recommendations to the Stem  
321 Cell Research Advisory Committee and the Commissioner of Public  
322 Health concerning the adoption of said guidelines, in whole or in part,  
323 in the form of regulations adopted pursuant to chapter 54.]

324 Sec. 5. Section 32-41aa of the 2014 supplement to the general statutes  
325 is repealed and the following is substituted in lieu thereof (*Effective*  
326 *October 1, 2014*):

327 For the purpose of this section and sections 32-41bb to 32-41dd,  
328 inclusive, as amended by this act:

329 [(1) "Administrative costs" means the costs paid or incurred by the  
330 administrator, including, but not limited to, peer review costs,  
331 professional fees, allocated staff costs and other out-of-pocket costs  
332 attributable to the administration and operation of the Connecticut  
333 Bioscience Innovation Fund.]

334 [(2)] (1) "Administrator" means Connecticut Innovations,  
335 Incorporated, in its capacity as administrator of the Connecticut  
336 Bioscience Innovation Fund established pursuant to section 32-41cc, as  
337 amended by this act.

338 [(3)] (2) "Advisory committee" means the Bioscience Innovation  
339 Advisory Committee established pursuant to section 32-41bb, as  
340 amended by this act.

341 [(4)] (3) "Early-stage business" means a business that has been in  
342 operation for not more than three years and is developing or testing a  
343 product or service that is (A) not yet available for commercial release,

344 or (B) commercially available in a limited manner, including, but not  
345 limited to, market testing of prototypes and clinical trials.

346 [(5)] (4) "Eligible recipient" means a duly accredited college or  
347 university, a nonprofit corporation or a for-profit start-up or early-  
348 stage business.

349 [(6)] (5) "Financial assistance" means any and all forms of grants,  
350 extensions of credit, loans or loan guarantees, equity investments or  
351 other forms of financing.

352 [(7)] (6) "Return on investment" means any and all forms of  
353 principal or interest payments, guarantee fees, returns on equity  
354 investments, royalties, options, warrants and debentures and all other  
355 forms of remuneration to the administrator in return for any financial  
356 assistance offered or provided.

357 Sec. 6. Subsection (e) of section 32-41bb of the 2014 supplement to  
358 the general statutes is repealed and the following is substituted in lieu  
359 thereof (*Effective October 1, 2014*):

360 (e) Notwithstanding any provision of the general statutes, it shall  
361 not constitute a conflict of interest for a trustee, director, partner,  
362 officer, manager, shareholder, proprietor, counsel or employee of an  
363 eligible recipient, or any individual with a financial interest in an  
364 eligible recipient, to serve as a member of the advisory committee,  
365 provided such trustee, director, partner, officer, manager, shareholder,  
366 proprietor, counsel, employee or individual shall abstain from  
367 deliberation, action or vote by the advisory committee in specific  
368 respect to such eligible recipient. All members of the advisory  
369 committee shall be deemed public officials and shall adhere to the code  
370 of ethics for public officials set forth in chapter 10.

371 Sec. 7. Subsections (d) and (e) of section 32-41cc of the 2014  
372 supplement to the general statutes are repealed and the following is  
373 substituted in lieu thereof (*Effective October 1, 2014*):

374 (d) The Connecticut Bioscience Innovation Fund shall be used (1) to  
375 provide financial assistance to eligible recipients as may be approved  
376 by the advisory committee pursuant to subsection (e) of this section,  
377 and (2) for the repayment of state bonds in such amounts as may be  
378 required by the State Bond Commission. [, and (3) to pay or reimburse  
379 the administrator for administrative costs pursuant to subsection (j) of  
380 this section.] Such financial assistance shall be awarded to further the  
381 development of bioscience, biomedical engineering, health information  
382 management, medical care, medical devices, medical diagnostics,  
383 pharmaceuticals, personalized medicine and other related disciplines  
384 that are likely to lead to an improvement in or development of  
385 services, therapeutics, diagnostics or devices that are commercializable  
386 and designed to advance the coordination, quality or efficiency of  
387 health care and lower health care costs, and that promise, directly or  
388 indirectly, to lead to job growth in the state in these or related fields.

389 (e) All expenditures from the Connecticut Bioscience Innovation  
390 Fund, except for [administrative costs reimbursed to the administrator  
391 pursuant to subsection (j) of this section and] amounts required for the  
392 repayment of state bonds in such amounts as may be required by the  
393 State Bond Commission, shall be approved by the advisory committee.  
394 Any such approval shall be (1) specific to an individual expenditure to  
395 be made, (2) for budgeted expenditures with such variations as the  
396 advisory committee may authorize at the time of such budget  
397 approval, or (3) for a financial assistance program to be administered  
398 by staff of the administrator, subject to limits, eligibility requirements  
399 and other conditions established by the advisory committee at the time  
400 of such program approval.

401 Sec. 8. Subsections (j) and (k) of section 32-41cc of the 2014  
402 supplement to the general statutes are repealed and the following is  
403 substituted in lieu thereof (*Effective October 1, 2014*):

404 [(j) Administrative costs shall be paid or reimbursed to the  
405 administrator from the Connecticut Bioscience Innovation Fund,  
406 provided the total of such administrative costs in any fiscal year shall

407 not exceed five per cent of the total amount of the allotted funding for  
408 such fiscal year as determined in the operating budget prepared  
409 pursuant to subsection (i) of this section. Nothing in sections 32-41aa  
410 and 32-41bb and this section shall require the administrator to risk or  
411 expend the funds of Connecticut Innovations, Incorporated in  
412 connection with the administration of the Connecticut Bioscience  
413 Innovation Fund.]

414 [(k)] (j) Not later than April 15, 2014, and annually thereafter, the  
415 administrator shall provide a report of the activities of the Connecticut  
416 Bioscience Innovation Fund to the advisory committee for its review  
417 and approval. Upon its approval, the advisory committee shall provide  
418 such report, in accordance with the provisions of section 11-4a, to the  
419 joint standing committees of the General Assembly having cognizance  
420 of matters relating to finance, revenue and bonding, appropriations,  
421 commerce, public health and higher education. Such report shall  
422 contain available information on the status and progress of the  
423 operations and funding of the Connecticut Bioscience Innovation Fund  
424 and the types, amounts and recipients of financial assistance awarded  
425 and any returns on investment.

426 Sec. 9. Subsection (c) of section 4-28e of the 2014 supplement to the  
427 general statutes is repealed and the following is substituted in lieu  
428 thereof (*Effective October 1, 2014*):

429 (c) (1) For the fiscal year ending June 30, 2001, disbursements from  
430 the Tobacco Settlement Fund shall be made as follows: (A) To the  
431 General Fund in the amount identified as "Transfer from Tobacco  
432 Settlement Fund" in the General Fund revenue schedule adopted by  
433 the General Assembly; (B) to the Department of Mental Health and  
434 Addiction Services for a grant to the regional action councils in the  
435 amount of five hundred thousand dollars; and (C) to the Tobacco and  
436 Health Trust Fund in an amount equal to nineteen million five  
437 hundred thousand dollars.

438 (2) For the fiscal year ending June 30, 2002, and each fiscal year

439 thereafter, disbursements from the Tobacco Settlement Fund shall be  
 440 made as follows: (A) To the Tobacco and Health Trust Fund in an  
 441 amount equal to twelve million dollars, except in the fiscal years  
 442 ending June 30, 2014, and June 30, 2015, said disbursement shall be in  
 443 an amount equal to six million dollars; (B) to the Biomedical Research  
 444 Trust Fund in an amount equal to four million dollars; (C) to the  
 445 General Fund in the amount identified as "Transfer from Tobacco  
 446 Settlement Fund" in the General Fund revenue schedule adopted by  
 447 the General Assembly; and (D) any remainder to the Tobacco and  
 448 Health Trust Fund.

449 (3) For each of the fiscal years ending June 30, 2008, to June 30, 2012,  
 450 inclusive, the sum of ten million dollars shall be disbursed from the  
 451 Tobacco Settlement Fund to the [Stem Cell] Regenerative Medicine  
 452 Research Fund established by section 19a-32e, as amended by this act,  
 453 for grants-in-aid to eligible institutions for the purpose of conducting  
 454 embryonic or human adult stem cell research.

This act shall take effect as follows and shall amend the following sections:		
Section 1	October 1, 2014	19a-32d(a)
Sec. 2	October 1, 2014	19a-32e
Sec. 3	October 1, 2014	19a-32f
Sec. 4	October 1, 2014	19a-32g
Sec. 5	October 1, 2014	32-41aa
Sec. 6	October 1, 2014	32-41bb(e)
Sec. 7	October 1, 2014	32-41cc(d) and (e)
Sec. 8	October 1, 2014	32-41cc(j) and (k)
Sec. 9	October 1, 2014	4-28e(c)

**CE** Joint Favorable Subst.